Edgar Filing: CYTOGEN CORP - Form 4

CYTOGEN O	CORP											
Form 4	7											
June 15, 2007									OMB AI	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287				
Check this if no long subject to Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er STATE 5. Filed pu ¹⁵ Section 17	Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						Expires: Estimated a burden hou response	rs per			
(Print or Type R	esponses)											
LOKAY KEVIN G S:			 Issuer Name and Ticker or Trading Symbol CYTOGEN CORP [CYTO] Date of Earliest Transaction 				g	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(M			(Month/Day/Year) 06/13/2007					X Director Officer (give below)	Officer (give title Other (specify			
				ndment, Date Original th/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
PRINCETO	N, NJ 08540								More than One Re			
(City)	(State)	(Zip)	Table	e I - Non-De	erivative S	ecurit	ties Acq	uired, Disposed o	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	 Execution any 		3.	4. Securit m(A) or Dis (D) (Instr. 3, 4 Amount	ies Ac sposed	quired l of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of		
Common Stock	06/13/2007			А	10,000 (1)	А	\$0	10,000	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CYTOGEN CORP - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock (2)	\$ 2	06/14/2007		A	10,000	06/14/2008	06/14/2017	common stock	10,000

Reporting Owners

Reporting Owner Name / Address		Relationships					
			10% Owner	Officer	Other		
LOKAY KEVIN G C/O CYTOGEN CORPORATIO 650 COLLEGE ROAD EAST, S PRINCETON, NJ 08540		Х					
Signatures							
/s/ Kevin G. Lokay 06/1	5/2007						

**Signature ofDateReporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Such shares of restricted common stock were issued pursuant to the terms of the Company's 2006 Equity Compensation Plan and vest on one (1) year anniversary.
- (2) Such options were granted pursuant to the terms of the Company's 2004 Non-Employee Director Stock Incentive Plan, and vest in full on the one-year anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.